U.S., Nov. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07234162) titled 'A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)' on Nov. 14.
Brief Summary: This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).
Study Start Date: May 13, 2024
Study Type: INTERVENTIONAL
Condition:
Peripheral T-cell Lymphoma
Interventio...